First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors
首次人体研究评估了强效、选择性抗CD73单克隆抗体oleclumab单独使用或与durvalumab联合使用治疗晚期实体瘤患者的疗效。
期刊:Cancer Immunology Immunotherapy
影响因子:5.1
doi:10.1007/s00262-023-03430-6
Bendell, Johanna; LoRusso, Patricia; Overman, Michael; Noonan, Anne M; Kim, Dong-Wan; Strickler, John H; Kim, Sang-We; Clarke, Stephen; George, Thomas J; Grimison, Peter S; Barve, Minal; Amin, Manik; Desai, Jayesh; Wise-Draper, Trisha; Eck, Steven; Jiang, Yu; Khan, Anis A; Wu, Yuling; Martin, Philip; Cooper, Zachary A; Elgeioushi, Nairouz; Mueller, Nancy; Kumar, Rakesh; Patel, Sandip Pravin